🔴 GRAIL is trading 6.5% down in pre-market after investors reassess a mixed FDA panel vote

GRAIL is trading at $101.50, down 6.47%, as investors reassess the mixed September 23, 2026 FDA advisory-panel recommendation.

• The panel backed Galleri’s benefit-risk profile 7–2, while efficacy support was narrower at 6–4; the recommendation is nonbinding.
• The decline likely reflects profit-taking and uncertainty after GRAIL’s earlier rally, despite unanimous safety support.